Zentalis Pharmaceuticals, Inc.

Symbol: ZNTL

NASDAQ

12.71

USD

Market price today

  • -3.1023

    P/E Ratio

  • 0.0250

    PEG Ratio

  • 901.90M

    MRK Cap

  • 0.00%

    DIV Yield

Zentalis Pharmaceuticals, Inc. (ZNTL) Financial Statements

On the chart you can see the default numbers in dynamics for Zentalis Pharmaceuticals, Inc. (ZNTL). Companys revenue shows the average of 0.002 M which is -0.143 % gowth. The average gross profit for the whole period is -0.603 M which is -1.766 %. The average gross profit ratio is 0.167 %. The net income growth for the company last year performance is 0.323 % which equals -0.591 % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of Zentalis Pharmaceuticals, Inc., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of 0.023. In the realm of current assets, ZNTL clocks in at 496.718 in the reporting currency. A significant portion of these assets, precisely 482.919, is held in cash and short-term investments. This segment shows a change of 0.104% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 2.681, if any, in the reporting currency. This indicates a difference of -87.362% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 43.15 in the reporting currency. This figure signifies a year_over_year change of -0.045%. Shareholder value, as depicted by the total shareholder equity, is valued at 437.284 in the reporting currency. The year over year change in this aspect is 0.008%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 0, with an inventory valuation of 0, and goodwill valued at 3.74, if any. The total intangible assets, if present, are valued at 0. Account payables and short-term debt are 14.93 and 2.62, respectively. The total debt is 45.77, with a net debt of 17.73. Other current liabilities amount to 51.54, adding to the total liabilities of 124.64. Lastly, the referred stock is valued at 0, if it exists.

common:word.in-mln

USD
Growth
TTM202320222021202020192018

balance-sheet.row.cash-and-short-term-investments

1945.06482.9437.4339.9
338.5
82.4
25.2

balance-sheet.row.short-term-investments

1503.43454.9394.3280.2
283.6
0
0

balance-sheet.row.net-receivables

4.74074.4
0.4
0.1
0.9

balance-sheet.row.inventory

15.630-7-4.4
0
0
0

balance-sheet.row.other-current-assets

33.713.814.610.9
6.2
1.5
0.6

balance-sheet.row.total-current-assets

1999.14496.7451.9350.8
345.1
84.1
26.7

balance-sheet.row.property-plant-equipment-net

171.941.750.152.8
3.6
2.8
0.3

balance-sheet.row.goodwill

14.943.73.73.7
3.7
3.7
3.7

balance-sheet.row.intangible-assets

0000
8.8
8.8
8.8

balance-sheet.row.goodwill-and-intangible-assets

14.943.73.73.7
12.5
12.5
12.5

balance-sheet.row.long-term-investments

26.842.721.237.5
1.3
0.2
0

balance-sheet.row.tax-assets

5.0810.314.17
0.6
0.8
0

balance-sheet.row.other-non-current-assets

40.626.8-1.82.6
2.3
2.2
1.5

balance-sheet.row.total-non-current-assets

259.3965.387.4103.7
20.5
18.6
14.3

balance-sheet.row.other-assets

0000
0
0
0

balance-sheet.row.total-assets

2258.53562539.3454.5
365.6
102.7
41

balance-sheet.row.account-payables

54.3114.911.211.6
8.7
4.3
3.4

balance-sheet.row.short-term-debt

9.632.62.21.5
0.9
0.8
0

balance-sheet.row.tax-payables

1.560.301
0.4
0
0

balance-sheet.row.long-term-debt-total

175.2143.145.244.5
1.1
0
0

Deferred Revenue Non Current

0000
-1.1
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

11.1---
-
-
-

balance-sheet.row.other-current-liab

179.1951.545.430.9
19
9.8
2.8

balance-sheet.row.total-non-current-liabilities

193.8955.348.646.1
3.6
4.2
2.5

balance-sheet.row.other-liabilities

0000
0
0
0

balance-sheet.row.capital-lease-obligations

179.9743.145.245.9
2
0.8
0

balance-sheet.row.total-liab

430.29124.6105.390
32.2
19.1
8.7

balance-sheet.row.preferred-stock

0000
0
141.7
59.8

balance-sheet.row.common-stock

0.270.10.10
0
0
2.3

balance-sheet.row.retained-earnings

-3147.89-888.6-596.4-359.6
-200.8
-83
-37.3

balance-sheet.row.accumulated-other-comprehensive-income-loss

0.942.2-1.4-0.1
0
-141.7
-0.1

balance-sheet.row.other-total-stockholders-equity

4974.361323.61031.7724.1
534.1
159.7
0.1

balance-sheet.row.total-stockholders-equity

1827.68437.3434364.5
333.4
76.8
24.8

balance-sheet.row.total-liabilities-and-stockholders-equity

2258.53562539.3454.5
365.6
102.7
41

balance-sheet.row.minority-interest

0.560.10.20.5
24.8
6.8
7.5

balance-sheet.row.total-equity

1828.23437.4434.2365
358.2
83.6
32.3

balance-sheet.row.total-liabilities-and-total-equity

2258.53---
-
-
-

Total Investments

1506.12457.6415.5317.7
283.6
0.2
0

balance-sheet.row.total-debt

182.645.845.245.9
2
0.8
0

balance-sheet.row.net-debt

-259.0317.72.1-13.8
-53
-81.6
-25.2

Cash Flow Statement

The financial landscape of Zentalis Pharmaceuticals, Inc. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of -0.253. The company recently extended its share capital by issuing 237.3, marking a difference of 18.644 compared to the previous year. Interestingly, a portion of the company's stock, specifically 0, was bought back by the company itself. This action resulted in a change of 0.000 from the previous year. Meanwhile, the company's account payables are currently standing at 10.92 in the reporting currency. The company's investing activities resulted in net cash usage, amounting to -44458000.000 in the reporting currency. This is a shift of -0.611 from the previous year. In the same period, the company recorded 1.39, 0, and 0, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated 0 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as 235.68, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM202320222021202020192018

cash-flows.row.net-income

-292.28-292.2-237.1-166.1
-118.5
-46.4
-23.4

cash-flows.row.depreciation-and-amortization

1.391.41.40.5
0.2
0.1
0.1

cash-flows.row.deferred-income-tax

-5.01-0.9-0.8-2.5
0
7.8
2.4

cash-flows.row.stock-based-compensation

54.8254.846.835.7
23.1
0.6
0.3

cash-flows.row.change-in-working-capital

5.865.913.316.6
7.8
6.5
-1.2

cash-flows.row.account-receivables

0000.4
-0.3
0.8
-0.3

cash-flows.row.inventory

0000.9
-5.5
-1.5
-1.9

cash-flows.row.account-payables

10.9210.915.513.9
14.3
7.1
1

cash-flows.row.other-working-capital

-5.05-5.1-2.31.3
-0.7
0.1
0

cash-flows.row.other-non-cash-items

27.423.112.6-38.4
0.6
-7.8
-2.4

cash-flows.row.net-cash-provided-by-operating-activities

-207.82000
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-0.58-0.6-2.5-6.1
-0.8
-0.4
-0.2

cash-flows.row.acquisitions-net

0.0400.1-14.3
18.4
0
0

cash-flows.row.purchases-of-investments

-549.18-549.2-533.2-363.5
-401
0
0

cash-flows.row.sales-maturities-of-investments

505.31505.3421.5365.8
116.9
0
0

cash-flows.row.other-investing-activites

-0.040-0.10
-18.4
0
0

cash-flows.row.net-cash-used-for-investing-activites

-44.46-44.5-114.2-18.1
-284.8
-0.4
-0.2

cash-flows.row.debt-repayment

0000
0
0
0

cash-flows.row.common-stock-issued

237.3237.3261179.7
327.8
81.8
0

cash-flows.row.common-stock-repurchased

0000
0
0
0

cash-flows.row.dividends-paid

0000
0
0
0

cash-flows.row.other-financing-activites

0.24235.70.3-1.1
32.7
0
9.5

cash-flows.row.net-cash-used-provided-by-financing-activities

237.3237.3261178.5
360.4
81.8
9.5

cash-flows.row.effect-of-forex-changes-on-cash

0-0.100
0
0
0

cash-flows.row.net-change-in-cash

-15.03-15-16.96.3
-11.2
42.3
-15

cash-flows.row.cash-at-end-of-period

449.512845.762.6
56.3
67.5
25.2

cash-flows.row.cash-at-beginning-of-period

464.5443.162.656.3
67.5
25.2
40.2

cash-flows.row.operating-cash-flow

-207.82-207.8-163.8-154.1
-86.8
-39.1
-24.3

cash-flows.row.capital-expenditure

-0.58-0.6-2.5-6.1
-0.8
-0.4
-0.2

cash-flows.row.free-cash-flow

-208.41-208.4-166.3-160.2
-87.6
-39.5
-24.5

Income Statement Row

Zentalis Pharmaceuticals, Inc.'s revenue saw a change of 0.000% compared with the previous period. The gross profit of ZNTL is reported to be -1.39. The company's operating expenses are 252.55, showing a change of 11.116% from the last year. The expenses for depreciation and amortization are 1.39, which is a -1.232% change from the last accounting period. Operating expenses are reported to be 252.55, which shows a 11.116% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a -0.318% year-over-year growth. The operating income is -253.94, which shows a 0.117% change when compared to the previous year. The change in the net income is 0.323%. The net income for the last year was -292.19.

common:word.in-mln

USD
Growth
TTM202320222021202020192018

income-statement-row.row.total-revenue

0000
0
0
0

income-statement-row.row.cost-of-revenue

1.391.41.40.5
0.2
0.1
0

income-statement-row.row.gross-profit

-1.39-1.4-1.4-0.5
-0.2
-0.1
0

income-statement-row.row.gross-profit-ratio

0000
0
0
0

income-statement-row.row.research-development

189.59---
-
-
-

income-statement-row.row.selling-general-administrative

64.35---
-
-
-

income-statement-row.row.selling-and-marketing-expenses

-0.34---
-
-
-

income-statement-row.row.other-expenses

45.5745.600
0
0
0

income-statement-row.row.operating-expenses

253.6252.6227.3216.5
118.8
46.8
23.8

income-statement-row.row.cost-and-expenses

253.94253.9227.3216.5
118.8
46.8
23.8

income-statement-row.row.interest-income

0.02000
0
0.5
0.4

income-statement-row.row.interest-expense

-5.9502.60
0
0
0

income-statement-row.row.selling-and-marketing-expenses

-0.34---
-
-
-

income-statement-row.row.total-other-income-expensenet

-22.95-23652
0.7
0.5
0.4

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-

income-statement-row.row.other-operating-expenses

45.5745.600
0
0
0

income-statement-row.row.total-operating-expenses

-22.95-23652
0.7
0.5
0.4

income-statement-row.row.interest-expense

-5.9502.60
0
0
0

income-statement-row.row.depreciation-and-amortization

-2.721.4-6-52
-0.7
0.1
0.1

income-statement-row.row.ebitda-caps

-222.75---
-
-
-

income-statement-row.row.operating-income

-299.51-253.9-227.3-216.5
-118.8
-46.8
-23.8

income-statement-row.row.income-before-tax

-276.89-276.9-221.3-164.6
-118.1
-46.4
-23.4

income-statement-row.row.income-tax-expense

-0.6-0.6-0.5-0.3
0.4
0
0

income-statement-row.row.net-income

-289.92-292.2-220.8-164.3
-118.5
-46.4
-21.1

Frequently Asked Question

What is Zentalis Pharmaceuticals, Inc. (ZNTL) total assets?

Zentalis Pharmaceuticals, Inc. (ZNTL) total assets is 562027000.000.

What is enterprise annual revenue?

The annual revenue is N/A.

What is firm profit margin?

Firm profit margin is 0.000.

What is company free cash flow?

The free cash flow is -2.945.

What is enterprise net profit margin?

The net profit margin is 0.000.

What is firm total revenue?

The total revenue is 0.000.

What is Zentalis Pharmaceuticals, Inc. (ZNTL) net profit (net income)?

The net profit (net income) is -292191000.000.

What is firm total debt?

The total debt is 45773000.000.

What is operating expences number?

The operating expences are 252552000.000.

What is company cash figure?

Enretprise cash is 28038000.000.